AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.090

+0.0033.45%

Volume:543.20K

Turnover:49.06K

Market Cap:70.58M

PE:-5.11

High:0.093

Open:0.088

Low:0.087

Close:0.087

52wk High:0.150

52wk Low:0.053

Shares:784.22M

Float Shares:351.37M

Volume Ratio:1.09

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-137.94%

ROA:-45.31%

PB:5.55

PE(LYR):-5.11

Loading ...

Overview Company News Filings

Neurizon Therapeutics - to Exclusively Buy Monepantel From Elanco With Specific Alternative Rights

THOMSON REUTERS

Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment

MT Newswires Live

Neurizon to host shareholder webinar on HEALEY ALS trial recruitment expansion

Neurizon expands HEALEY ALS trial Regimen I to 240 participants

Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study

Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%

MT Newswires Live

Neurizon wins ethics approval for NUZ-001 Phase 1 oral liquid study

Neurizon Therapeutics Ltd - Receives Ethics Approval for Phase 1 Nuz-001 Oral Liquid Formulation Study

THOMSON REUTERS

Neurizon appoints Ross Murdoch independent non-executive director

Neurizon Therapeutics Ltd-Neurizon Strengthens Board for the Next Growth Phase

THOMSON REUTERS

Neurizon Therapeutics Ltd-Appendix 4C & Quarterly Update

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million

Neurizon Therapeutics Ltd - Announces Placement of Entitlement Offer Shortfall to Raise ~a$2.7 Mln

THOMSON REUTERS

Neurizon Therapeutics Ltd - Total Amount to Be Raised Under Entitlement Offer Is ~a$8.5 Mln

THOMSON REUTERS

Neurizon publishes investor deck outlining NUZ-001 ALS program in HEALEY platform trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/NUZ.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.09,"timestamp":1791436320000,"preClose":0.087,"halted":0,"volume":543197,"delay":0,"changeRate":0.03448275862068969,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":784215600,"eps":-0.0176,"marketStatus":"Closed","change":0.003,"latestTime":"10-08 16:12:00 AEDT","open":0.088,"high":0.093,"low":0.087,"amount":49058,"amplitude":0.068966,"askPrice":0.094,"askSize":200000,"bidPrice":0.09,"bidSize":35000,"shortable":3,"etf":0,"ttmEps":-0.0176,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791500400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.087,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":1.09284,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.087,"auctionPrice":0.087,"auctionVolume":38,"auction":3,"marketStatus":"盘后竞价","timestamp":1791349799229}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-45.31%","roe":"-137.94%","lyrEps":-0.0176,"volumeRatio":1.09284,"shares":784215600,"dividePrice":0,"high":0.093,"amplitude":0.068966,"preClose":0.087,"low":0.087,"week52Low":0.053,"pbRate":"5.55","psRate":"4.01","week52High":0.15,"institutionHeld":0,"latestPrice":0.09,"committee":-0.702128,"eps":-0.0176,"divideRate":0,"volume":543197,"delay":0,"ttmEps":-0.0176,"open":0.088,"prevYearClose":0.085,"prevWeekClose":0.08,"prevMonthClose":0.078,"prevQuarterClose":0.078,"fiveDayClose":0.075,"twentyDayClose":0.078,"sixtyDayClose":0.063,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644879521","title":"Neurizon Therapeutics - to Exclusively Buy Monepantel From Elanco With Specific Alternative Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2644879521","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644879521?lang=en_us&edition=fundamental","pubTime":"2026-06-17 07:08","pubTimestamp":1781651280,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUE5MMMQF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642230058","title":"Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2642230058","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642230058?lang=en_us&edition=fundamental","pubTime":"2026-06-12 08:05","pubTimestamp":1781222711,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics (ASX:NUZ) said it dosed over 50% of participants in the first regimen of a trial evaluating NUZ-001 for the treatment of amyotrophic lateral sclerosis, or ALS, according to a Fri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","LENZ","BK4139","BK4007","BK7096","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638890966","title":"Neurizon to host shareholder webinar on HEALEY ALS trial recruitment expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2638890966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638890966?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:55","pubTimestamp":1779893714,"startTime":"0","endTime":"0","summary":"Neurizon will host a shareholder webinar on May 28 to discuss the expansion of Regimen I in the HEALEY ALS Platform Trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL7qRkzs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638952980","title":"Neurizon expands HEALEY ALS trial Regimen I to 240 participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2638952980","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638952980?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:42","pubTimestamp":1779838967,"startTime":"0","endTime":"0","summary":"Neurizon expanded Regimen I of the HEALEY ALS Platform Trial for NUZ-001 to 240 participants from 160.Topline results were not presented; last patient dosing is projected for Q2 2027, with topline data expected early Q3 2027.Change aims to preserve study power while producing a larger, more consistent dataset to support regulatory and partnering discussions.Cohort now set at 180 treated patients, 60 placebo controls; 113 assigned, 74 dosed as of May 22, 2026.Funding needs through completion are expected to remain unchanged, supported by philanthropic contributions, with only a modest rise in total trial cost.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL6t9cXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635122705","title":"Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635122705","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635122705?lang=en_us&edition=fundamental","pubTime":"2026-05-13 09:57","pubTimestamp":1778637448,"startTime":"0","endTime":"0","summary":"May 13 (Reuters) - Neurizon Therapeutics Ltd ::*RECEIVES ETHICS APPROVAL FOR PHASE 1 NUZ-001 ORAL LIQUID FORMULATION STUDY*Further company coverage: NUZ.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((R","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nRSD7f2kC3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635222831","title":"Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635222831","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635222831?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:56","pubTimestamp":1778633814,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis , according to a Wednesday filing with the Australian bourse.ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.The study is scheduled to start in the third quarter and be completed in the fourth quarter.Neurizon Therapeutics shares gained 3% in recent Wednesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","BK4139","BK7096","BK4007","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635722921","title":"Neurizon wins ethics approval for NUZ-001 Phase 1 oral liquid study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722921","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635722921?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:40","pubTimestamp":1778629242,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics received human research ethics clearance from Bellberry HREC for Phase 1 study of NUZ-001 oral liquid formulation in healthy volunteers.Trial targets start in Q3 2026, completion in Q4 2026.Study will compare oral liquid versus tablet under fed, fasted conditions to support pharmacokinetic, safety, tolerability data for ALS development program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4V96BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635296162","title":"Neurizon Therapeutics Ltd - Receives Ethics Approval for Phase 1 Nuz-001 Oral Liquid Formulation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635296162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635296162?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:20","pubTimestamp":1778628007,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634389422","title":"Neurizon appoints Ross Murdoch independent non-executive director","url":"https://stock-news.laohu8.com/highlight/detail?id=2634389422","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634389422?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:32","pubTimestamp":1778455925,"startTime":"0","endTime":"0","summary":"Neurizon appointed Ross Murdoch as independent non-executive director, effective immediately, as it advances NUZ-001 in the HEALEY ALS Platform Trial.Murdoch brings more than 30 years of pharmaceutical and biotech leadership, including senior roles at AstraZeneca, GlaxoSmithKline, Shire Pharmaceuticals; currently CEO and president of Extractas Bioscience.Michael Thurn retired from board, effective immediately, following previously announced transition from managing director and CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on May 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nNDLxhXrf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203347892.USD","LU0545562505.USD","LU0306806265.USD","LU1481600234.SGD","LU1302929846.USD","LU0971552830.HKD","LU0971552673.USD","LU1400636574.HKD","LU1481599808.USD","LU0109981661.USD","SG9999001176.SGD","IE00BQJZX424.USD","LU0058720904.USD","BK5011","LU0306807586.USD","LU1035777561.USD","LU1064927863.SGD","LU0161305163.EUR","LU0225283273.USD","LU0985481810.HKD","LU0321505439.SGD","SGXZ57979304.SGD","LU1098665638.USD","LU1983299246.USD","LU0225771236.USD","LU0321505868.SGD","IE00B3T34201.USD","LU0575583348.USD","LU0557290698.USD","IE0034235071.USD","LU1202635105.USD","LU2089984988.USD","LU0203345920.USD","GSK.UK","LU1228905037.USD","LU0289739699.SGD","LU1400636657.SGD","LU0987226296.USD","LU1015430645.USD","LU1487256676.USD","IE00BWDBJ516.SGD","LU2468319806.SGD","LU1046248800.SGD","NUZ.AU","SG9999001176.USD","SG9999013999.USD","BK7096","LU0211331839.USD","LU2646069778.SGD","LU0225284248.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633054691","title":"Neurizon Therapeutics Ltd-Neurizon Strengthens Board for the Next Growth Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2633054691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633054691?lang=en_us&edition=fundamental","pubTime":"2026-05-08 07:06","pubTimestamp":1778195187,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUECH3XD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557317","title":"Neurizon Therapeutics Ltd-Appendix 4C & Quarterly Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631557317?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:38","pubTimestamp":1777505905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE3FTPKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627225246","title":"BRIEF-Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627225246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627225246?lang=en_us&edition=fundamental","pubTime":"2026-04-16 09:42","pubTimestamp":1776303766,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 MillionApril 16  - Neurizon Therapeutics Ltd NUZ.AX:ANNOUNCES PLACEMENT OF ENTITLEMENT OFFER SHORTFALL TO RAISE ~A$2.7 MILLIONTOTAL AMOUNT TO BE RAISED UNDER ENTITLEMENT OFFER IS ~A$8.5 MILLIONFurther company coverage: NUZ.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Y0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627147256","title":"Neurizon Therapeutics Ltd - Announces Placement of Entitlement Offer Shortfall to Raise ~a$2.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2627147256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627147256?lang=en_us&edition=fundamental","pubTime":"2026-04-16 07:28","pubTimestamp":1776295709,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40Y0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627025614","title":"Neurizon Therapeutics Ltd - Total Amount to Be Raised Under Entitlement Offer Is ~a$8.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2627025614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627025614?lang=en_us&edition=fundamental","pubTime":"2026-04-16 07:28","pubTimestamp":1776295709,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40Y0JF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626716701","title":"Neurizon publishes investor deck outlining NUZ-001 ALS program in HEALEY platform trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2626716701","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626716701?lang=en_us&edition=fundamental","pubTime":"2026-04-10 16:01","pubTimestamp":1775808083,"startTime":"0","endTime":"0","summary":"Neurizon outlined progress for lead asset NUZ-001, an oral small molecule being advanced in ALS through Regimen I of HEALEY ALS Platform Trial.Trial timeline targets enrollment completion in Q3-Q4 2026, with topline data expected in Q3 2027.Neurizon flagged supply-chain de-risking via Elanco, with commercial supply agreement execution expected in Q2 2026 and API supply secured to end of HEALEY trial.Cash at Mar. 31, 2026 was AUD 16.7 million, with convertible note debt of AUD 5.6 million, implying net cash of AUD 11.1 million.Capital structure snapshot listed 708,878,681 shares outstanding, with market capitalization of AUD 60.3 million and enterprise value of AUD 49.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL2XkZvJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}]}}